Lite Strategy Inc (LITS) Stock Price, Quote & News

Company Profile

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 369 7100

Website: www.litestrategy.com

Address:

9920 Pacific Heights Blvd., Suite 150, San Diego, United States

s3v3nSph3r3 Jun. 21 at 5:46 PM

$LITS That CEO is paid 1M per year for a 25M MC company. He spends 1M on things that will exist no matter what but has no real value at that exact moment, so certainly not 1M. I expect LTC to go in the twenty like Charlee Lee said years ago. Still huge wall forming against LTC. Can $LITS drop more than 50% again from that bad LitVM money burning news if BTC goes to 52k-50k again. Yes, and the CEO will take 1M anyway even if the MC is worth 10M after that

0 · Reply

focafoca99 Jun. 19 at 12:51 PM

$LITS is attending a panel at the Litecoin Foundation Summit in Amsterdam on June 22.

0 · Reply

s3v3nSph3r3 Jun. 18 at 7:39 PM

$LITS will we get a friday market open of -25% if ltc goes to 41$ or under on $LITS ? For sure!!! it would had been so much better without that bad news from today presented like a beautiful girl but in fact it was a girl but not a born girl idk how to say it correctly.. I need to say that it can go to 0.45$ or 50% from 0.92 when they annonced the news. GG management team, now i begin to understand what the shareholder of your pharma company was thinking

0 · Reply

CashCow11 Jun. 18 at 7:38 PM

$LITS bankruptcy soon. Investing in Litvm was the stupidest idea ever when you are not a profitable company. Just fattening each other's pockets

0 · Reply

s3v3nSph3r3 Jun. 18 at 7:08 PM

$LITS Just sold 5k share at 0.84$ still own a bunch and planning to add more when the litvm lemming finally say it was a mistake.. under 0.70$ :) i hope it will reverse up but the odds are with me :) ♦️🙌♦️

0 · Reply

s3v3nSph3r3 Jun. 18 at 6:51 PM

$LITS Keep some cash to add under 0.70$ because people who wanted that company to invest 1M in litvm does not have the cash to support the price of the stock at that price. ♦️🙌♦️

0 · Reply

Statistical Jun. 18 at 3:54 PM

$LITS reverse splits coming in the next 6 months.

0 · Reply

R3JS Jun. 18 at 2:12 PM

$LITS dividends soon when this launches and then Charlie Lee replaces Michael Saylor. Too easy to see the future has been preplanned.

2 · Reply

Ultra100 Jun. 18 at 1:52 PM

$LITS awesome

0 · Reply

s3v3nSph3r3 Jun. 18 at 1:43 PM

$LITS bang told you . What a stupid call to put 1M in ltvVM. 😢

1 · Reply

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

LTC

2026-06-18T12:48:16.000Z - 5 days ago

Lite Strategy leads strategic investment in LitVM

Jun 18, 2026, 8:30 AM EDT - 5 days ago

Lite Strategy Leads Strategic Investment in LitVM

May 13, 2026, 8:30 AM EDT - 5 weeks ago

Lite Strategy Reports Fiscal 2026 Third Quarter Results

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Lite Strategy Quarterly report: Q3 2026

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Lite Strategy Earnings release: Q3 2026

2026-02-17T14:40:22.000Z - 4 months ago

Lite Strategy reports Q2 EPS (82c) vs. (40c) last year

2026-02-17T14:00:57.000Z - 4 months ago

Lite Strategy to continue to evaluate strategic investments in 2H of 2026

Feb 17, 2026, 8:50 AM EST - 4 months ago

Lite Strategy Reports Fiscal 2026 Second Quarter Results

Feb 17, 2026, 7:00 AM EST - 4 months ago

Lite Strategy Earnings release: Q2 2026

Feb 17, 2026, 7:00 AM EST - 4 months ago

Lite Strategy Quarterly report: Q2 2026

Jan 27, 2026, 7:00 AM EST - 5 months ago

Lite Strategy Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 6 months ago

Lite Strategy Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 6 months ago

Lite Strategy Proxy statement: Proxy Filing

2025-11-19T16:15:44.000Z - 7 months ago

Lite Strategy names acting CEO Justin File to role on a permanent basis

2025-11-17T14:05:45.000Z - 7 months ago

Lite Strategy reports Q1 results, highlights launch of $100M Litecoin Treasury

Nov 14, 2025, 4:00 PM EST - 7 months ago

Lite Strategy Quarterly report: Q1 2026

2025-10-29T13:12:45.000Z - 8 months ago

Lite Strategy announces $25M share repurchase program

2025-10-08T20:50:10.000Z - 9 months ago

Lite Strategy files to sell 780,497 shares of common stock for holders

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Lite Strategy Registration statement: Registration Filing

Sep 26, 2025, 7:00 AM EDT - 9 months ago

Lite Strategy Annual report: Q4 2025

Sep 10, 2025, 9:00 AM EDT - 10 months ago

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

Aug 26, 2025, 8:00 AM EDT - 10 months ago

Lite Strategy Registration statement: Registration Filing

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Lite Strategy Registration statement: Registration Filing

Aug 5, 2025, 8:00 AM EDT - 11 months ago

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Jul 24, 2025, 8:00 PM EDT - 11 months ago

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul 22, 2025, 4:35 PM EDT - 1 year ago

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 18, 2025, 8:30 AM EDT - 1 year ago

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

May 13, 2025, 4:05 PM EDT - 1 year ago

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

May 13, 2025, 4:00 PM EDT - 1 year ago

Lite Strategy Earnings release: Q3 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lite Strategy Quarterly report: Q3 2025

Feb 12, 2025, 4:12 PM EST - 1 year ago

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Feb 12, 2025, 12:00 AM EST - 1 year ago

Lite Strategy Earnings release: Q2 2025

Feb 12, 2025, 12:00 AM EST - 1 year ago

Lite Strategy Quarterly report: Q2 2025

Dec 20, 2024, 7:00 AM EST - 1 year ago

Lite Strategy Proxy statement: Proxy Filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

Lite Strategy Proxy statement: Proxy Filing

Nov 12, 2024, 4:05 PM EST - 1 year ago

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Nov 12, 2024, 4:00 PM EST - 1 year ago

Lite Strategy Earnings release: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

Lite Strategy Quarterly report: Q1 2025

Sep 19, 2024, 4:01 PM EDT - 1 year ago

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Sep 18, 2024, 6:00 PM EDT - 1 year ago

Lite Strategy Earnings release: Q4 2024

Sep 18, 2024, 6:00 PM EDT - 1 year ago

Lite Strategy Annual report: Q4 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

Jul 22, 2024, 8:30 AM EDT - 2 years ago

MEI Pharma to Consider Strategic Alternatives

May 9, 2024, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

Lite Strategy Quarterly report: Q3 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Lite Strategy Earnings release: Q3 2024

Apr 16, 2024, 1:30 PM EDT - 2 years ago

Lite Strategy Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 11, 2024, 8:02 AM EDT - 2 years ago

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

$MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia$

Mar 26, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Feb 20, 2024, 7:00 AM EST - 2 years ago

Lite Strategy Registration statement: Registration Filing

Feb 13, 2024, 5:05 PM EST - 2 years ago

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Feb 13, 2024, 4:00 PM EST - 2 years ago

Lite Strategy Quarterly report: Q2 2024

Feb 13, 2024, 4:00 PM EST - 2 years ago

Lite Strategy Earnings release: Q2 2024

Jan 16, 2024, 5:00 PM EST - 2 years ago

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Dec 11, 2023, 12:00 PM EST - 2 years ago

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Nov 15, 2023, 8:35 AM EST - 2 years ago

Lite Strategy Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Lite Strategy Quarterly report: Q1 2024

Nov 9, 2023, 4:00 PM EST - 2 years ago

Lite Strategy Earnings release: Q1 2024

Nov 8, 2023, 8:00 AM EST - 2 years ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Nov 8, 2023, 7:00 AM EST - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Nov 6, 2023, 4:57 PM EST - 2 years ago

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 2, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 1, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 17, 2023, 5:33 PM EDT - 2 years ago

MEI Pharma Recommends Stockholders Not to Consent

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 2, 2023, 6:00 AM EDT - 2 years ago

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 28, 2023, 5:00 PM EDT - 2 years ago

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Lite Strategy Earnings Call Transcript: Q4 2023

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Lite Strategy Annual report: Q4 2023

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Lite Strategy Earnings release: Q4 2023

Sep 26, 2023, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 21, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 18, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Sep 18, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 15, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Aug 16, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Jul 23, 2023, 2:30 PM EDT - 3 years ago

MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 19, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 18, 2023, 9:00 AM EDT - 3 years ago

MEI Pharma Responds to Anson and Cable Car

Jul 17, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 17, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Jul 13, 2023, 4:05 PM EDT - 3 years ago

MEI Pharma Postpones Special Meeting of Shareholders

Jul 11, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 7, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 5, 2023, 8:30 AM EDT - 3 years ago

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jun 29, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 15, 2023, 12:08 PM EDT - 3 years ago

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 14, 2023, 7:01 PM EDT - 3 years ago

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Jun 13, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Jun 2, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

s3v3nSph3r3 Jun. 21 at 5:46 PM

0 · Reply

focafoca99 Jun. 19 at 12:51 PM

$LITS is attending a panel at the Litecoin Foundation Summit in Amsterdam on June 22.

0 · Reply

s3v3nSph3r3 Jun. 18 at 7:39 PM

0 · Reply

CashCow11 Jun. 18 at 7:38 PM

$LITS bankruptcy soon. Investing in Litvm was the stupidest idea ever when you are not a profitable company. Just fattening each other's pockets

0 · Reply

s3v3nSph3r3 Jun. 18 at 7:08 PM

0 · Reply

s3v3nSph3r3 Jun. 18 at 6:51 PM

$LITS Keep some cash to add under 0.70$ because people who wanted that company to invest 1M in litvm does not have the cash to support the price of the stock at that price. ♦️🙌♦️

0 · Reply

Statistical Jun. 18 at 3:54 PM

$LITS reverse splits coming in the next 6 months.

0 · Reply

R3JS Jun. 18 at 2:12 PM

$LITS dividends soon when this launches and then Charlie Lee replaces Michael Saylor. Too easy to see the future has been preplanned.

2 · Reply

Ultra100 Jun. 18 at 1:52 PM

$LITS awesome

0 · Reply

s3v3nSph3r3 Jun. 18 at 1:43 PM

$LITS bang told you . What a stupid call to put 1M in ltvVM. 😢

1 · Reply

s3v3nSph3r3 Jun. 18 at 1:04 PM

$LITS This is a bad move to invest LITVM when they could buy 1M of LTC under 50$ each or buy 1M of their shares under 1$. LITVM would had existed without that investment and people in LTC care about money not smart contract when your money can be controlled by anyting other than you. We want LTC to produce a cube of data instead of a spread sheet to multiply the number of transactions per block to something VISA would fear. We want privacy. We want quantum resistance. But 1 thing for sure, we dont care about smart contract. Go in the solana scam if you do. Im not happy, vote that ceo out and elect me instead, ill push that sotck over 100$ :) (I wont sell my LITS$, LTC is going over 80$ again but we are not happy short term) Sell if you dont have the diamonds hand cause it can hurt ♦️🙌♦️

0 · Reply

TheTaurusBull38 Jun. 18 at 12:53 PM

$LITS this thing is giving me whiplash

0 · Reply

rac0258 Jun. 18 at 12:38 PM

$LTC.X and $LITS have joined forces to develop Layer 2 smart contracts. LITS now has a seat at the LitVM table. https://tradevae.com/news/stock-markets/lite-strategy-leads-1m-strategic-round-for-litecoin-layer-2-project-litvm/

0 · Reply

Xvool Jun. 17 at 7:16 PM

$LITS Company Tweeted 1 hour ago 8:30am ET tomorrow ! Watch for news to drop 👉🚨 https://x.com/LiteStrategy $ICCM $YMAT $SNBR $SDOT

0 · Reply

s3v3nSph3r3 Jun. 17 at 6:09 PM

$LITS I just bought another 10 LTC today but no shares of $LITS , push the price lower and im adding :) ♦️🙌♦️

0 · Reply

TheTaurusBull38 Jun. 17 at 1:44 PM

$LITS jumped in here with 25000 shares. Let’s go

1 · Reply

s3v3nSph3r3 Jun. 17 at 5:40 AM

$LITS 1.47M shares traded today out of 25M.. wait.. i saw that pattern before.. Now i remember the diamonds hands ♦️🙌♦️

0 · Reply

OneNightHolder Jun. 17 at 12:13 AM

$OTLK $LITS $AKBA $ABVC thes are the holds for tonight. We will check back tomorrow morning.

0 · Reply

XRPisREALmoney Jun. 16 at 10:33 PM

$LITS $AKBA $OTLK $ABVC these are the overnight holds for today.

0 · Reply

R3JS Jun. 16 at 6:57 PM

$LTC.X $LITS lits up 11% why do whales make it so easy to see what’s coming 😂🍋

1 · Reply

s3v3nSph3r3 Jun. 16 at 5:26 PM

$LITS bought another 1000 shares of $LITS at 0.85555$ and 25 LTC today . LTC under 50$ and LITS under 1$ what else can i do :) ♦️🙌♦️

0 · Reply

s3v3nSph3r3 Jun. 15 at 10:06 PM

$LITS nice little up today +/- 10%. The insider dumped months ago, we are now ready for the LTC bull market of a lifetime and people can't still see the value in $LITS . We can get in at the best prices :) under 1$ USD its a GIFT

0 · Reply

Market Cap	28.17M
Revenue (ttm)	0.00
Net Income (ttm)	-15.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	200,743
Avg Vol	436,006
Day's Range	N/A - N/A
Shares Out	34.03M
Stochastic %K	67%
Beta	0.21
Analysts	Hold
Price Target	N/A